- Home
- ZI vs XENE Comparison
ZI vs XENE Comparison
Compare ZI & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZI
- XENE
- Stock Information
- Founded
- ZI 2007
- XENE 1996
- Country
- ZI United States
- XENE Canada
- Employees
- ZI N/A
- XENE N/A
- Industry
- ZI Computer Software: Prepackaged Software
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- ZI Technology
- XENE Health Care
- Exchange
- ZI Nasdaq
- XENE Nasdaq
- Market Cap
- ZI 3.5B
- XENE 3.3B
- IPO Year
- ZI 2020
- XENE 2014
- Fundamental
- Price
- ZI $9.65
- XENE $39.73
- Analyst Decision
- ZI Hold
- XENE Strong Buy
- Analyst Count
- ZI 20
- XENE 7
- Target Price
- ZI $12.05
- XENE $57.00
- AVG Volume (30 Days)
- ZI 4.9M
- XENE 445.7K
- Earning Date
- ZI 02-25-2025
- XENE 02-27-2025
- Dividend Yield
- ZI N/A
- XENE N/A
- EPS Growth
- ZI N/A
- XENE N/A
- EPS
- ZI 0.02
- XENE N/A
- Revenue
- ZI $1,221,600,000.00
- XENE N/A
- Revenue This Year
- ZI N/A
- XENE N/A
- Revenue Next Year
- ZI N/A
- XENE $1,599.99
- P/E Ratio
- ZI $399.90
- XENE N/A
- Revenue Growth
- ZI N/A
- XENE N/A
- 52 Week Low
- ZI $7.65
- XENE $35.53
- 52 Week High
- ZI $17.70
- XENE $50.99
- Technical
- Relative Strength Index (RSI)
- ZI 39.14
- XENE 51.79
- Support Level
- ZI $9.98
- XENE $38.22
- Resistance Level
- ZI $10.64
- XENE $39.73
- Average True Range (ATR)
- ZI 0.34
- XENE 1.21
- MACD
- ZI -0.04
- XENE 0.01
- Stochastic Oscillator
- ZI 1.98
- XENE 68.12
About ZI ZoomInfo Technologies Inc
ZoomInfo Technologies Inc provides a go-to-market intelligence platform for sales and marketing teams. Its cloud-based go-to-market data and insights platform deliver comprehensive and high-quality intelligence and analytics to provide sales and marketing professionals with accurate information and insights on the organizations and professionals. Nearly all of its revenue is derived from the United States.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.